Back to search

Spain· ES:82549

VALGANCICLOVIR KERN PHARMA 450 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG

A valganciclovir product containing valganciclovir, registered in Spain by Kern Pharma S.L.. The same ATC class is registered in 18 of our 19 countries.

ATC J05AB14

Checked against AEMPS CIMA (Spain) on

Informational only — not a medical device.

SOURCE REGISTER · ESAEMPS CIMA (Spain)normalisedVALGANCICLOVIR KERN PHARMA 450 MG COM…ATCJ05AB14REGISTER NO.ES:82549PACKS LISTED0CHECKEDAugust 12, 2026

Where it is registered

Valganciclovir is registered in 18 of 19 countries.

Countries holding a registration under ATC J05AB14 (valganciclovir), each read from that country’s own register.

  • This record: Spain, from AEMPS CIMA (Spain)
  • 11 of them publish a price we can compare per daily dose

Valganciclovir · ATC J05AB14

18 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of valganciclovir costs, country by country.

Normalised to the WHO defined daily dose (0.9 g), the median price runs from $3.83 in United States to $35.27 in Italy — a ×9.2 gap.

  • 4 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
  • US figures are pharmacy acquisition cost (CMS NADAC), not retail

Valganciclovir · price per daily dose (0.9 g)

USD · FX 28 Sept 2026

  • IT Italy$35.27
  • CH Switzerland$35.18
  • FR France$22.39
  • US United States$3.83 (acquisition cost)
Median listed price per WHO defined daily dose, in each market that publishes a price. US = pharmacy acquisition cost (CMS NADAC), not a retail price. Open the full comparison

The record

At a glance

AEMPS CIMA (Spain)
Active substance
valganciclovir
Manufacturer
Kern Pharma S.L.
Country
Spain (ES)
ATC code
J05AB14
ATC class
Valganciclovir
Defined daily dose
0.9 g, O
Reimbursed
Not published by this register
Source register
AEMPS CIMA (Spain)
Last checked
August 12, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

283 interactions on record for valganciclovir.

Graded by severity as the source publishes them — 8 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Valganciclovir · interactions on record

283 records

  • 8 severe
  • 193 moderate
  • 82 info

Most severe, free to view

  • CladribineL01BB04severe
  • TrospiumA03AB20moderate
  • Amphotericin BA07AA07moderate
  • TrospiumG04BD09moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Valganciclovir in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All valganciclovir products

Authorised across Europe · EMA

The same active substance is authorised in 28 EEA countries. Names it is sold under:

  • Austria · Valcyte, Valganciclovir +pharma
  • Belgium · Valcyte, Valganciclovir Sandoz
  • Bulgaria · Алваноцит, Валцит
  • Cyprus · Valcyte, Valganciclovir Accord
  • Czechia · Cytevix, Valcyte
  • Germany · Valcyte, Valganaxiro
  • Denmark · Valcyte, Valganciclovir "medical Valley"
  • Estonia · Valganciclovir Accord, Valganciclovir Sandoz
  • Finland · Valcyte, Valganciclovir Accord
  • France · Rovalcyte, Valganciclovir Accord
  • United Kingdom (Northern Ireland) · Valcyte, Valganciclovir Accord Healthcare
  • Greece · Vagotrosin, Valcyte
  • Croatia · Alvanocyt, Valcyte
  • Hungary · Valcyte, Valdamin
  • Ireland · Valcyte, Valganciclovir Accord Healthcare
  • Iceland · Valcyte, Valganciclovir Medical Valley
  • Italy · Valcyte, Valganciclovir Accord
  • Lithuania · Valganciclovir Accord, Valganciclovir Sandoz
  • Luxembourg · Valcyte
  • Latvia · Valcyte, Valganciclovir Accord
  • Netherlands · Alvanocyt, Valcyte
  • Norway · Valcyte, Valganciclovir Accord
  • Poland · Ceglar, Valcyte
  • Portugal · Rovalcyte, Valganciclovir Accord
  • Romania · Valganciclovir Zentiva
  • Sweden · Valcyte, Valganciclovir Accord
  • Slovenia · Ganaxa, Valcyte
  • Slovakia · Valdamin

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of AEMPS CIMA (Spain). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/eeb60456-8be5-4db8-8ad2-bf9a8004a5ea
GET /v1/drugs/eeb60456-8be5-4db8-8ad2-bf9a8004a5ea?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cpresc": "Diagnóstico Hospitalario",
  "estado": "{\"aut\":1508919402000,\"rev\":1760614815000}",
  "nregistro": "82549",
  "substance": "valganciclovir"
}

See everything about valganciclovir.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.